NR updated reportCrystal Research Associates Issues Updated Report on BELLUS Health Inc.
Dec 16, 2010 (ACCESSWIRE via COMTEX News Network) --
Disease-Modifying Pharmaceutical Treatments and Nutraceuticals New York -- Crystal Research Associates, LLC announced today that it has issued an updated Executive Informational Overview® (EIO®) on BELLUS Health Inc. (BLU-TSX). The full 44-page report can be found at www.crystalra.com.
BELLUS Health Inc. ("BELLUS Health" or "the Company") is a global health company focused on the research and development of innovative health solutions for critical, unmet medical needs. The Company's pharmaceutical pipeline targets disorders for which there are no known cures.
BELLUS Health's most advanced pharmaceutical candidate is KIACTA (eprodisate) to treat Amyloid A (AA) amyloidosis, a disease marked by an abnormal accumulation of certain proteins that can cause organ dysfunction, organ failure, and even death. In December 2010, KIACTA entered a confirmatory Phase III trial funded by Celtic Therapeutics, a global private equity firm, under an April 2010 agreement between BELLUS Health and Celtic. The Company's pharmaceutical pipeline also includes NRM8499, a prodrug for Alzheimer's disease (AD) that entered a Phase I trial in March 2010.
Additionally, through a wholly owned subsidiary, OVOS Natural Health Inc., the Company markets a clinically tested nutraceutical called VIVIMIND (tramiprosate/homotaurine) to protect memory function. VIVIMIND is available online and has been granted approval for sale in Canada, Italy, and Spain.
Be the first to hear about Crystal Research's new report releases and upcoming media coverage. Follow us on Twitter at https://www.twitter.com/crystalresearch or visit our blog to stay up-to-date on industry and company news for clients under our research coverage.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality research on small- and mid-cap companies. The firm is led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by the international financial media for his years of work on Wall Street and for providing consistent award-winning analyses and developing long-term relationships on both the buy-side and sell-side. He has been consistently ranked on Wall Street among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally, Mr. Kraws has been 5-Star Ranked for top biotechnology stock performance by Starmine.
Crystal Research Associates' unique and novel product, the Executive Informational Overview® (EIO®), is free of investment ratings, target prices, and forward-looking financial models. The EIO® presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO® details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, West Palm Beach, Montreal, and Toronto.
Website: https://www.crystalra.com
Crystal Research Associates, LLC
Karen B. Goldfarb
email: karen@crystalra.com
Crystal Research Associates, LLC
Jeffrey J. Kraws
email: jeff@crystalra.com
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements, including limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed in the Company's periodic reports and other forms filed from time to time. These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no responsibility to update any of the forward-looking statements in this release. Crystal Research Associates has been compensated by the Company in cash of eighty thousand U.S. dollars for its services in creating and updating the base report, for quarterly updates, and for printing costs.
Executive Informational Overview and EIO are registered trademarks of Crystal Research Associates, LLC. KIACTA and VIVIMIND are trademarks of BELLUS Health Inc.
Copyright 2010 ACCESSWIRE